Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
4.9
Journals
Marine Drugs
Special Issues
Marine Natural Products against Neurological Diseases and Brain Injuries
share announcement

Marine Natural Products against Neurological Diseases and Brain Injuries

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 5841

Special Issue Editors

Prof. Dr. II Soo Moon

E-Mail Website
Guest Editor
Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea
Interests: protein structure and dynamics; protein conformational disorders; drug design; protein–protein interaction; neurodegenerative diseases; molecular modeling
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Md. Abdul Hannan

E-Mail Website
Guest Editor
Department of Biochemistry and Molecular Biology, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh
Interests: bioactive natural products with neuroprotective potentials; molecular neuropharmacology; system pharmacology; functional foods; computational biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bioactive natural products are promising for the development of novel therapeutic agents. Although terrestrial sources have always been given priority over marine sources, the latter have recently received equal attention due to their highly diverse bioactive molecules with unique chemical structure and bioactivity. Marine organisms such as microorganisms, algae, fungi, sponges, cnidarians, and mollusks are abundant in diverse molecules that are primarily synthesized to cope with various environmental stimuli. However, these bioactive compounds have shown numerous pharmacological potentials, including neuroprotective, antioxidant, anti-inflammatory, immunomodulatory, and antiproliferative properties. With the growing prevalence of oxidative stress- and inflammation-mediated chronic brain diseases, including Alzheimer’s, Parkinson’s, and Huntington’s diseases, and other neurological diseases, natural product researchers and drug designers have been concentrating their attention on the discovery and development of novel therapeutic leads from marine natural products or their skeletons. Many of these compounds modulate various molecular targets of brain-specific biochemical and signaling pathways, suggesting their therapeutic significance in the management of neurological diseases, brain injuries, and tumors.

This Special Issue will cover the isolation and characterization of novel compounds from marine organisms; the bioactivity of already known molecules; structure–activity relationships; and the mechanisms of neuroprotection against various toxic insults representing in vitro and in vivo models of neurodegeneration, brain injury, psychological disorders, neuropathic pain, and tumors. Both original research and review papers are welcome.

Prof. Dr. II Soo Moon
Prof. Dr. Md. Abdul Hannan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Marine organisms
  • Bioactive natural products
  • Molecular neuropharmacology
  • Neuroprotection
  • Neurodegenerative disorders, ischemic stroke, and acute brain injury
  • Neuropathic pain
  • Psychological disorders
  • Brain tumors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 4630 KiB  
Article
RKC-B1 Blocks Activation of NF-κB and NLRP3 Signaling Pathways to Suppress Neuroinflammation in LPS-Stimulated Mice
by Man Liu, Ying-Lin Yang, Shan-Shan Zhang, Dong-Ni Liu, Lian-Hua Fang, Guan-Hua Du and Yue-Hua Wang
Mar. Drugs 2021, 19(8), 429; https://doi.org/10.3390/md19080429 - 28 Jul 2021
Cited by 5 | Viewed by 2305
Abstract
RKC-B1 is a novel fermentation product obtained from the marine micromonospora FIM02-523A. Thus far, there have been few reports about the pharmacological activity of RKC-B1. In our present study, we investigated the anti-neuroinflammatory effects and the possible mechanism of RKC-B1 in LPS-stimulated mice. [...] Read more.
RKC-B1 is a novel fermentation product obtained from the marine micromonospora FIM02-523A. Thus far, there have been few reports about the pharmacological activity of RKC-B1. In our present study, we investigated the anti-neuroinflammatory effects and the possible mechanism of RKC-B1 in LPS-stimulated mice. After treatment with RKC-B1, RNA-seq transcriptome of the cerebral cortex tissue was conducted to find the differentially expressed genes (DEGs). Inflammatory cytokines and proteins were evaluated by ELISA and WB. In RNA-seq analysis, there were 193 genes screened as core genes of RKC-B1 for treatment with neuroinflammation. The significant KEGG enrichment signaling pathways of these core genes were mainly included TNF signaling pathway, IL-17 signaling pathway, NOD-like receptor signaling pathway, NF-κB signaling pathway and others. The corresponding top five KEGG enrichment pathways of three main clusters in PPI network of core genes were closely related to human immune system and immune disease. The results showed that RKC-B1 reduced the levels of pro-inflammatory factors (IL-6, IL-1β, MCP-1, and ICAM-1) and the expression of COX2 in cerebral cortex tissue. Additionally, we found that the anti-neuroinflammation activity of RKC-B1 might be related to suppress activating of NF-κB and NLRP3/cleaved caspase-1 signaling pathways. The current findings suggested that RKC-B1 might be a promising anti-neuroinflammatory agent. Full article
(This article belongs to the Special Issue Marine Natural Products against Neurological Diseases and Brain Injuries)
►▼ Show Figures

Figure 1

18 pages, 3922 KiB  
Article
Lyophilization Serves as an Effective Strategy for Drug Development of the α9α10 Nicotinic Acetylcholine Receptor Antagonist α-Conotoxin GeXIVA[1,2]
by Zhiguo Li, Xiaolu Han, Xiaoxuan Hong, Xianfu Li, Jing Gao, Hui Zhang and Aiping Zheng
Mar. Drugs 2021, 19(3), 121; https://doi.org/10.3390/md19030121 - 25 Feb 2021
Cited by 6 | Viewed by 2580
Abstract
α-Conotoxin GeXIVA[1,2] is a highly potent and selective antagonist of the α9α10 nicotinic acetylcholine receptor (nAChR) subtype. It has the advantages of strong efficacy, no tolerance, and no effect on motor function, which has been expected help patients with neuropathic pain. However, drug [...] Read more.
α-Conotoxin GeXIVA[1,2] is a highly potent and selective antagonist of the α9α10 nicotinic acetylcholine receptor (nAChR) subtype. It has the advantages of strong efficacy, no tolerance, and no effect on motor function, which has been expected help patients with neuropathic pain. However, drug development for clinical use is severely limited owing to its instability. Lyophilization is applied as the most preferred method to solve this problem. The prepared lyophilized powder is characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), and Fourier transform infrared spectroscopy (FTIR). Molecular simulation is also used to explore the internal distribution and forces formed in the system. The analgesic effect on paclitaxel-induced neuropathic pain following single and 14-day repeated administrations are evaluated by the von Frey test and the tail-flick test. Trehalose combined with mannitol in a ratio of 1:1 is employed as the excipients in the determined formulation, where trehalose acts as the stabilizer and mannitol acts as the bulking agent, according to the results of DSC, PXRD, and FTIR. Both GeXIVA[1,2] (API) and GeXIVA[1,2] lyophilized powder (formulation) could produce stable analgesic effect. These results indicated that GeXIVA[1,2] lyophilized powder could improve the stability and provide an effective strategy to push it into clinical use as a new analgesic drug. Full article
(This article belongs to the Special Issue Marine Natural Products against Neurological Diseases and Brain Injuries)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop